BBD BioPhenix USA LLC.

CRO developing toxicity adn efficacy assays in zebrafish in a High Content Screening way and under GLP´s to select safer and more efficient drug candidates early in the process, gaining time and money. Clients send their candidates and we screen them for different toxicity assays or for efficacy, offering them data in weeks time cost efficiently for a better selection of candidates in between in vitro and in vivo assays, as a fee for service.